Commentary

Video

Dr Besse on Results From the CARMEN-LC03 Trial in Nonsquamous NSCLC

Author(s):

Benjamin Besse, MD

Fact checked by:

Kyle Doherty
Conference|IASLC World Conference on Lung Cancer

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Benjamin Besse, MD, PhD, director, clinical research, and medical oncologist at Institute Gustave Roussy, discusses findings from the phase 3 CARMEN-LC03 trial (NCT04154956), which is examining tusamitamab ravtansine in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).

Related Videos
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
T. Jeroen N. Hiltermann, MD, of University of Groningen
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Related Content
Renal Cell Carcinoma | Image Credit: © Crystal light - stock.adobe.com
September 17th 2024

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Marjorie Green, MD
September 17th 2024

Patritumab Deruxtecan Meets PFS End Point in Pretreated EGFR-Mutant NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Nabil Saba, MD
September 17th 2024

Neoadjuvant Chemotherapy Could Enhance Organ Preservation in Nasal and Paranasal Sinus Squamous Cell Carcinoma

Meredith McKean, MD, of Sarah Cannon Research Institute
September 16th 2024

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status